Safety, Pharmacokinetics and Efficacy of GDC-0084 in Newly-diagnosed Glioblastoma Multiforme
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03522298|
Recruitment Status : Active, not recruiting
First Posted : May 11, 2018
Last Update Posted : March 11, 2020
This protocol has a 2-part design:
This phase 2 study is an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics (PK) and clinical activity of GDC-0084 in patients with newly-diagnosed glioblastoma multiforme (GBM) with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and initial chemoradiation with temozolomide (TMZ).
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma, Adult||Drug: GDC-0084||Phase 2|
Stage 1 Dose-Escalation and Maximum Tolerated Dose The dose-escalation portion of the study (Stage 1) will use a standard "3 + 3" design to determine the MTDs for QD and intermittent dosing schedules.
The MTDs for QD and intermittent dosing of GDC-0084 will be determined in 3 steps: QD (Step 1), QOD (Step 2) and daily dosing for 3 consecutive days of the week (3 days on/4 days off) (Step 3). All 3 steps will follow the same dose-escalation rules as described below. Each step and each dose cohort within each step will consist of newly recruited patients with all patients receiving the dose to which they are originally assigned.
Approximately 6 - 12 patients with newly diagnosed GBM will be enrolled in Stage 1.
The MTD for QD dosing will be determined. The initial dose level for QD dosing will be 60 mg (Dose Level 0). This dose is based on the phase 1 findings outlined in the rationale in the protocol, adding 1 dose level to test for a potential MTD increase.
Dose-escalation will occur in Stage 1:
- The initial dose (Dose Level 0) for QD MTD determination in Step 1 will be 60 mg. Dose levels will increase in 15 mg steps;
- The dose-escalation portion of the study (Stage 1) will use a standard "3 + 3" design to assess the safety, tolerability, and PK of GDC-0084 administered orally in 28-day cycles;
Decisions regarding dose-escalation and selection will be made by a Cohort Review Committee (CRC).
All AEs, including DLTs, will be reported, with severity assessed according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
After determination of the MTD, patients continue to receive their protocol-assigned dose levels of GDC-0084 until progression of their disease or an unacceptable toxicity, whichever occurs first.
Stage 2 Expansion stage (2) of the study will be a three-arm, randomized, open-label expansion study to further characterize the safety, tolerability and PK of GDC-0084 as well as to provide a preliminary assessment of single-agent activity of GDC-0084 in patients with GBM. Approximately 20 patients will be enrolled in the expansion cohort in 2 treatment arms (10 per am) to examine the PK of GDC-0084 in fed and fasted-conditions, according to the defined study eligibility criteria.
Stage 2 of the study will be initiated with recruitment of new patients as soon as the MTD has been determined.
Patients enrolled in Stage 2 may continue the study at the dose allocated until disease progression or unacceptable toxicity.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||32 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This phase 2 study comprises an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, RP2D, PK and clinical activity of GDC 0084 in patients with newly-diagnosed GBM with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and initial chemoradiation with TMZ.|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor GDC-0084 Administered to Patients With Glioblastoma Multiforme Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide|
|Actual Study Start Date :||May 15, 2018|
|Estimated Primary Completion Date :||March 30, 2020|
|Estimated Study Completion Date :||December 30, 2020|
Experimental: Dose Escalation and Expansion Cohorts
This is an open-label study.
Patients in Stage 1 will be enrolled and sequentially assigned to a dose cohort.
The initial cohort will receive an oral dose of 60 mg GDC-0084 QD (4 x 15 mg capsules). Patients of future dose cohorts will receive GDC-0084 at increasing levels with 15 mg steps until a dose-limiting toxicity occurs (DLT) occurs. The dose level where <1/3 of the patients exhibit a DLT will be determined the Maximum Tolerated Dose (MTD).
In stage 1, dose escalation will occur for QD dosing.
In stage 2, the expansion phase, patients will receive doses of oral GDC-0084 at the MTD in stage 1, until disease progression or an unacceptable toxicity, whichever occurs first.
Patients will be randomized in a 1:1 ratio to fed or fasted schedules.
Patients will be dosed orally with GDC-0084 capsules (15-mg each) at the dose and schedule to which they are assigned.
- Dose limiting toxicities (DLTs) [ Time Frame: 12 months ]The recommended Phase 2 dose and schedule. DLTs according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
- Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: 24 months ]TEAEs defined as any AE occurring or worsening on/after the first study drug dose and within 28 days after the last dose date. AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA).
- Incidence of serious adverse events (SAEs) [ Time Frame: 24 months ]AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA).
- Incidence of treatment-emergent Grade 3/4 clinical laboratory abnormalities. [ Time Frame: 24 months ]Clinical laboratory values will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, for applicable tests.
- Change in electrocardiogram (ECG) parameter QTc. [ Time Frame: 24 months ]The number and percentage of patients with an increase of QTc to a value ≥ 500 msec or a change from baseline of at least 60 msec will be presented overall and by visit.
- Change in left ventricular ejection fraction (LVEF). [ Time Frame: 24 months ]The number and percentage of patients with a drop in LVEF to a value of ≤ 45% from baseline will be presented overall and by visit.
- Progression-free survival interval using RANO Criteria. [ Time Frame: 24 months ]
- Overall survival using RANO Criteria. [ Time Frame: 24 months ]
- Pharmacokinetics of GDC-0084 as area under the curve from time 0 to last measurable time point (AUC0-last) and/or area under the curve from time 0 to infinity (AUC0-inf). [ Time Frame: 24 months ]
- Pharmacokinetics of GDC-0084 as maximum (Cmax) and minimum concentration (Cmin). [ Time Frame: 24 months ]
- Pharmacokinetics of GDC-0084 as time to reach Cmax (Tmax). [ Time Frame: 24 months ]
- Pharmacokinetics of GDC-0084 as half-life. [ Time Frame: 24 months ]
- Change in FDG-PET uptake in tumor and normal brain tissue in response to GDC-0084 in patients with measurable disease. [ Time Frame: 24 months ]
- Disease control rate measured as the proportion of patients achieving a confirmed best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) according to RANO criteria. [ Time Frame: 24 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03522298
|United States, California|
|University of California Los Angeles - Jonsson Comprehensive Cancer Center|
|Los Angeles, California, United States, 90095|
|United States, Colorado|
|University of Colorado Cancer Center|
|Aurora, Colorado, United States, 80045|
|United States, Massachusetts|
|Dana Farber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|United States, New Jersey|
|John Theurer Cancer Center at Hackensack University Medical Center|
|Hackensack, New Jersey, United States, 07601|
|United States, Oklahoma|
|University of Oklahoma Health Sciences Center (Stephenson Cancer Center)|
|Oklahoma City, Oklahoma, United States, 73104|
|United States, Texas|
|MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Study Director:||James Garner, MD||Kazia Therapeutics Limited|